Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Q2 Revenues Fall 38 Percent, Net Loss Narrows

NEW YORK (GenomeWeb News) - GeneNews today said second-quarter revenues tumbled 38 percent as R&D spending dropped 16 percent and net loss decreased by 7 percent.
Total receipts for the three months ended June 30 decreased to CA$540,000 (US$508,700) from CA$873,000 year over year.
The Toronto-based company said all its revenue for the second quarter of 2007 came from a $2 million prostate cancer biomarker research project it signed with an Asian biomedical consortium that it disclosed yesterday. Revenue for the prior-year period resulted from a collaboration agreement with Pfizer that ended in the first fiscal quarter of 2007.
R&D spending decreased to CA$1.8 million from CA$2.1 million year over year.
Net loss dipped to CA$1.8 million from CA$1.9 million in the year-ago period.
GeneNews said it had around CA$16.6 million in cash and cash equivalents as of June 30.
The company, which said its focus is currently on biomarker research and development for diagnostic products, did not offer revenue projections for the full year.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.